Which has preferable earnings and valuation, LQDA or HRMY?

Harmony Biosciences has higher revenue and earnings than Liquidia. Harmony Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $450.91M 13.95 -$68.92M $1.37 51.29 Harmony Biosciences $959.90M 2.34 $158.69M $3.08 12.50

Does the media refer more to LQDA or HRMY?

In the previous week, Liquidia had 9 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat Liquidia's score of 0.53 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, HRMY or LNTH?

Lantheus has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Harmony Biosciences $959.90M 2.34 $158.69M $3.08 12.50 Lantheus $1.54B 4.27 $233.56M $4.14 24.35

Does the media favor HRMY or LNTH?

In the previous week, Lantheus had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 9 mentions for Lantheus and 6 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat Lantheus' score of 1.28 indicating that Harmony Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harmony Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Lantheus 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BLTE or HRMY?

In the previous week, Harmony Biosciences had 2 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Harmony Biosciences and 4 mentions for Belite Bio. Harmony Biosciences' average media sentiment score of 1.54 beat Belite Bio's score of -0.75 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Negative Harmony Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer AMRX or HRMY?

In the previous week, Harmony Biosciences had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Harmony Biosciences and 1 mentions for Amneal Pharmaceuticals. Harmony Biosciences' average media sentiment score of 1.54 beat Amneal Pharmaceuticals' score of 0.59 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor DFTX or HRMY?

In the previous week, Definium Therapeutics had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 8 mentions for Definium Therapeutics and 6 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat Definium Therapeutics' score of 0.62 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Definium Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Harmony Biosciences (HRMY) Competitors

$38.50 +0.35 (+0.92%)

Closing price 04:00 PM Eastern

Extended Trading

$38.51 +0.01 (+0.01%)

As of 04:16 PM Eastern

Compare

HRMY vs. LQDA, LNTH, BLTE, AMRX, and DFTX

Should you buy Harmony Biosciences stock or one of its competitors? Harmony Biosciences's main competitors and comparable companies include Liquidia (LQDA), Lantheus (LNTH), Belite Bio (BLTE), Amneal Pharmaceuticals (AMRX), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Harmony Biosciences compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Harmony Biosciences has higher revenue and earnings than Liquidia. Harmony Biosciences is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$450.91M	13.95	-$68.92M	$1.37	51.29
Harmony Biosciences	$959.90M	2.34	$158.69M	$3.08	12.50

Liquidia has a net margin of 30.74% compared to Harmony Biosciences' net margin of 18.88%. Liquidia's return on equity of 149.65% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
Harmony Biosciences	18.88%	20.06%	14.15%

64.5% of Liquidia shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Liquidia presently has a consensus target price of $98.08, indicating a potential upside of 39.58%. Harmony Biosciences has a consensus target price of $45.50, indicating a potential upside of 18.18%. Given Liquidia's stronger consensus rating and higher probable upside, research analysts clearly believe Liquidia is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Liquidia had 9 more articles in the media than Harmony Biosciences. MarketBeat recorded 15 mentions for Liquidia and 6 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat Liquidia's score of 0.53 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	9 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Liquidia beats Harmony Biosciences on 11 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to Lantheus?

Harmony Biosciences (NASDAQ:HRMY) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Harmony Biosciences has a net margin of 18.88% compared to Lantheus' net margin of 17.69%. Lantheus' return on equity of 28.10% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harmony Biosciences	18.88%	20.06%	14.15%
Lantheus	17.69%	28.10%	14.35%

Harmony Biosciences currently has a consensus target price of $45.50, indicating a potential upside of 18.18%. Lantheus has a consensus target price of $108.11, indicating a potential upside of 7.25%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Harmony Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

In the previous week, Lantheus had 3 more articles in the media than Harmony Biosciences. MarketBeat recorded 9 mentions for Lantheus and 6 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat Lantheus' score of 1.28 indicating that Harmony Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harmony Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Lantheus	7 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

86.2% of Harmony Biosciences shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 11.0% of Harmony Biosciences shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Harmony Biosciences has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than Harmony Biosciences. Harmony Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harmony Biosciences	$959.90M	2.34	$158.69M	$3.08	12.50
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.35

Summary

Lantheus beats Harmony Biosciences on 9 of the 15 factors compared between the two stocks.

How does Harmony Biosciences compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, analyst recommendations and dividends.

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Belite Bio presently has a consensus target price of $205.80, suggesting a potential upside of 29.54%. Harmony Biosciences has a consensus target price of $45.50, suggesting a potential upside of 18.18%. Given Belite Bio's stronger consensus rating and higher possible upside, analysts clearly believe Belite Bio is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Harmony Biosciences has a net margin of 18.88% compared to Belite Bio's net margin of 0.00%. Harmony Biosciences' return on equity of 20.06% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Harmony Biosciences	18.88%	20.06%	14.15%

Belite Bio has a beta of -1.22, suggesting that its stock price is 222% less volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

In the previous week, Harmony Biosciences had 2 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Harmony Biosciences and 4 mentions for Belite Bio. Harmony Biosciences' average media sentiment score of 1.54 beat Belite Bio's score of -0.75 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Harmony Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Harmony Biosciences has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Harmony Biosciences	$959.90M	2.34	$158.69M	$3.08	12.50

Summary

Harmony Biosciences beats Belite Bio on 11 of the 15 factors compared between the two stocks.

How does Harmony Biosciences compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Amneal Pharmaceuticals has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

In the previous week, Harmony Biosciences had 5 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 6 mentions for Harmony Biosciences and 1 mentions for Amneal Pharmaceuticals. Harmony Biosciences' average media sentiment score of 1.54 beat Amneal Pharmaceuticals' score of 0.59 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Amneal Pharmaceuticals currently has a consensus price target of $17.67, indicating a potential downside of 0.64%. Harmony Biosciences has a consensus price target of $45.50, indicating a potential upside of 18.18%. Given Harmony Biosciences' higher possible upside, analysts plainly believe Harmony Biosciences is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Harmony Biosciences has lower revenue, but higher earnings than Amneal Pharmaceuticals. Harmony Biosciences is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.88	$72.06M	$0.49	36.29
Harmony Biosciences	$959.90M	2.34	$158.69M	$3.08	12.50

Harmony Biosciences has a net margin of 18.88% compared to Amneal Pharmaceuticals' net margin of 5.05%. Harmony Biosciences' return on equity of 20.06% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%
Harmony Biosciences	18.88%	20.06%	14.15%

Summary

Harmony Biosciences beats Amneal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Harmony Biosciences compare to Definium Therapeutics?

Definium Therapeutics (NASDAQ:DFTX) and Harmony Biosciences (NASDAQ:HRMY) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Definium Therapeutics has a beta of 2.23, meaning that its stock price is 123% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market.

27.9% of Definium Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 2.4% of Definium Therapeutics shares are held by insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Definium Therapeutics had 2 more articles in the media than Harmony Biosciences. MarketBeat recorded 8 mentions for Definium Therapeutics and 6 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.54 beat Definium Therapeutics' score of 0.62 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Definium Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Definium Therapeutics presently has a consensus price target of $63.00, suggesting a potential upside of 45.60%. Harmony Biosciences has a consensus price target of $45.50, suggesting a potential upside of 18.18%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Definium Therapeutics is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30

Harmony Biosciences has a net margin of 18.88% compared to Definium Therapeutics' net margin of 0.00%. Harmony Biosciences' return on equity of 20.06% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Definium Therapeutics	N/A	-84.01%	-63.66%
Harmony Biosciences	18.88%	20.06%	14.15%

Harmony Biosciences has higher revenue and earnings than Definium Therapeutics. Definium Therapeutics is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A
Harmony Biosciences	$959.90M	2.34	$158.69M	$3.08	12.50

Summary

Harmony Biosciences beats Definium Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Harmony Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRMY vs. The Competition

Export

Metric	Harmony Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.24B	$12.42B	$7.29B	$12.71B
Dividend Yield	N/A	2.62%	2.54%	10.79%
P/E Ratio	12.50	780.42	271.39	24.10
Price / Sales	2.34	789.54	604.58	77.05
Price / Cash	12.00	15.47	29.03	36.90
Price / Book	2.55	10.42	11.18	6.40
Net Income	$158.69M	$2.79B	$3.46B	$348.28M
7 Day Performance	0.94%	2.25%	1.98%	0.92%
1 Month Performance	9.00%	4.72%	7.32%	5.10%
1 Year Performance	1.69%	7.07%	24.76%	16.16%

Harmony Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRMY Harmony Biosciences	4.4997 of 5 stars	$38.50 +0.9%	$45.50 +18.2%	+0.8%	$2.24B	$959.90M	12.50	200	Positive News
LQDA Liquidia	4.2814 of 5 stars	$77.70 +4.4%	$98.08 +26.2%	+155.7%	$6.66B	$450.91M	56.72	50	Insider Trade
LNTH Lantheus	3.3527 of 5 stars	$100.91 0.0%	$108.11 +7.1%	+71.7%	$6.59B	$1.54B	24.37	1,193	Positive News
BLTE Belite Bio	3.2253 of 5 stars	$163.21 +0.3%	$205.80 +26.1%	+150.1%	$6.53B	N/A	N/A	10
AMRX Amneal Pharmaceuticals	2.892 of 5 stars	$18.42 +1.5%	$17.67 -4.1%	+86.8%	$5.80B	$3.02B	37.59	8,500

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRMY) was last updated on 8/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harmony Biosciences (HRMY) Competitors

HRMY vs. LQDA, LNTH, BLTE, AMRX, and DFTX

How does Harmony Biosciences compare to Liquidia?

Summary

How does Harmony Biosciences compare to Lantheus?

Summary

How does Harmony Biosciences compare to Belite Bio?

Summary

How does Harmony Biosciences compare to Amneal Pharmaceuticals?

Summary

How does Harmony Biosciences compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harmony Biosciences (HRMY) Competitors

HRMY vs. LQDA, LNTH, BLTE, AMRX, and DFTX

How does Harmony Biosciences compare to Liquidia?

Which has more volatility & risk, LQDA or HRMY?

Which has preferable earnings and valuation, LQDA or HRMY?

Is LQDA or HRMY more profitable?

Do institutionals & insiders believe in LQDA or HRMY?

Do analysts rate LQDA or HRMY?

Does the media refer more to LQDA or HRMY?

Summary

How does Harmony Biosciences compare to Lantheus?

Is HRMY or LNTH more profitable?

Do analysts rate HRMY or LNTH?

Does the media favor HRMY or LNTH?

Do insiders and institutionals believe in HRMY or LNTH?

Which has more risk & volatility, HRMY or LNTH?

Which has preferable valuation and earnings, HRMY or LNTH?

Summary

How does Harmony Biosciences compare to Belite Bio?

Do institutionals and insiders have more ownership in BLTE or HRMY?

Do analysts rate BLTE or HRMY?

Is BLTE or HRMY more profitable?

Which has more risk and volatility, BLTE or HRMY?

Does the media refer more to BLTE or HRMY?

Which has better valuation and earnings, BLTE or HRMY?

Summary

How does Harmony Biosciences compare to Amneal Pharmaceuticals?

Which has more risk and volatility, AMRX or HRMY?

Does the media prefer AMRX or HRMY?

Do institutionals & insiders believe in AMRX or HRMY?

Do analysts prefer AMRX or HRMY?

Which has stronger valuation & earnings, AMRX or HRMY?

Is AMRX or HRMY more profitable?

Summary

How does Harmony Biosciences compare to Definium Therapeutics?

Which has more volatility & risk, DFTX or HRMY?

Do insiders and institutionals have more ownership in DFTX or HRMY?

Does the media favor DFTX or HRMY?

Do analysts prefer DFTX or HRMY?

Is DFTX or HRMY more profitable?

Which has stronger earnings & valuation, DFTX or HRMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRMY vs. The Competition

Harmony Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools